Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Copanlisib + WEHI-539 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Copanlisib | Aliqopa | BAY80-6946|BAY806946 | PIK3CA inhibitor 29 PIK3CD inhibitor 27 | Aliqopa (copanlisib) is a selective PIK3CA and PIK3CD inhibitor that prevents activation of Akt, resulting in inhibition of cell cycle progression and increased apoptosis (PMID: 24013662, PMID: 25528022). |
| WEHI-539 | BCL-XL inhibitor 15 | WEHI-539 is a selective inhibitor of BCL-XL that stimulates apoptotic responses in cells, resulting in killing of tumor cells (PMID: 23603658, PMID: 32752193). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PIK3CA H1047R | colorectal cancer | no benefit | Copanlisib + WEHI-539 | Preclinical - Cell culture | Actionable | In a preclinical study, the addition of WEHI-539 to Aliqopa (copanlisib) did not result in greater inhibition of growth in murine-derived colorectal cancer organoids harboring PIK3CA H1047R in culture (PMID: 40635161). | 40635161 |
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|